L. Bellido

Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

G. Martín, J. Cruz, L. Bellido, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma

Á. Santos-Briz, J. Cañueto, M. Ludeña, 2020, The American Journal of dermatopathology.

Case 3. Upper limb lymphangiosarcoma following breast cancer therapy.

A. Ocaña, C. Rodríguez, J. Cruz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autoimmune Responses in Oncology: Causes and Significance

M. Fuentes, Pablo Juanes-Velasco, Ángela-Patricia Hernández, 2021, International journal of molecular sciences.

Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays

C. E. Pedreira, Patrick F. Braz, Breno L. Galves, 2021, Cancers.

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

J. Martín-Broto, C. Valverde, A. de Juan, 2018, The oncologist.

Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.

J. López-Novoa, A. Ocaña, M. Pericacho, 2007, Cancer letters.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

A. Arance, E. Espinosa, C. Montagut, 2021, Nature Communications.

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

E. Espinosa, L. Fernández-Morales, Á. Rodríguez-Lescure, 2023, Melanoma research.